Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
09 Novembre 2023 - 2:00PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will present a corporate overview
and information on STAR-0215 and STAR-0310 at the Jefferies London
Healthcare Conference on Wednesday, November 15, at 10:30am GMT in
London, UK.
A webcast of the presentation can be accessed at the following
link: https://wsw.com/webcast/jeff287/atxs/1884032. An archived
replay of the presentation will be available in the investors
section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109732128/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Astria Therapeutics (NASDAQ:ATXS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024